RSV-NET data showed that RSV hospitalization rates among infants aged 0 to 7 months were an estimated 43% (95% confidence ...

The American Academy of Pediatrics has said childhood vaccines are carefully studied in randomized controlled trials — ...

The data suggest that the most severe RSV disease among infants up to seven months old is preventable, the CDC said, adding that it is important to protect infants, ideally within ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Investment includes $1.5 billion in capital expenditures to expand manufacturing and $500 million dedicated to R&D focused on high-impact innovations.

After the monoclonal antibody nirsevimab (Beyfortus) became available to prevent respiratory syncytial virus (RSV) in infants ...

Beyfortus, which has been approved for use in the European Union, US, China, Japan, among several countries globally, received its marketing authorisation approval from India’s Central Drugs ...

Dr Reddy’s Laboratories expands its strategic partnership with Sanofi Healthcare India to introduce a novel drug, Beyfortus (nirsevimab), in India. Beyfortus contains the monoclonal antibody, ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India. Containing monoclonal antibody ...

Hyderabad-based pharma company Dr Reddy’s Laboratories has expanded its strategic partnership with Sanofi Healthcare India Private Limited (SHIPL) to introduce a novel drug, Beyfortus (nirsevimab), in ...

Dr Reddy's Laboratories on Monday said it has expanded its partnership with Sanofi Healthcare to introduce a novel drug for the prevention of lower respiratory tract disease in newborns. The company ...